SpliceBio
A Spanish genetic medicines company utilising protein splicing to develop the next generation of gene therapies.
The company’s proprietary platform enables efficient delivery of large genes with adeno-associated vectors (AAV), overcoming the most fundamental challenge in the quest to curing a broad range of genetic diseases. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of protein engineering research.
Latest SpliceBio News & Features
17 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze